UBS downgrades Siemens Healthineers citing China market challenges By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 26 2024
0mins
Should l Buy ?
Source: Investing.com
UBS Downgrade: Siemens Healthineers AG has been downgraded by UBS from a "buy" to a "neutral" rating due to concerns over its medium-term growth prospects, particularly in the Chinese market where competition from local firms is increasing.
Financial Forecast Revision: UBS has revised its financial forecasts for Siemens Healthineers, expecting group revenues to decline by 1% to 3% from 2025 to 2028, and has lowered its price target to €51, reflecting the anticipated impact of competitive pressures and a reduced growth outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
